Your browser is no longer supported. Please, upgrade your browser.
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E19.18 EPS (ttm)10.51 Insider Own0.20% Shs Outstand259.37M Perf Week0.54%
Market Cap51.87B Forward P/E15.68 EPS next Y12.86 Insider Trans-15.31% Shs Float258.52M Perf Month-0.02%
Income2.76B PEG1.96 EPS next Q3.00 Inst Own93.60% Short Float1.58% Perf Quarter-7.62%
Sales6.41B P/S8.09 EPS this Y128.00% Inst Trans0.38% Short Ratio1.83 Perf Half Y-12.00%
Book/sh34.62 P/B5.82 EPS next Y6.87% ROA23.90% Target Price260.73 Perf Year-27.85%
Cash/sh26.91 P/C7.49 EPS next 5Y9.80% ROE32.60% 52W Range185.32 - 283.45 Perf YTD-14.71%
Dividend- P/FCF17.33 EPS past 5Y45.30% ROI26.40% 52W High-29.95% Beta0.64
Dividend %- Quick Ratio4.20 Sales past 5Y43.20% Gross Margin88.10% 52W Low7.14% ATR4.08
Employees3400 Current Ratio4.40 Sales Q/Q13.80% Oper. Margin44.50% RSI (14)47.85 Volatility2.28% 1.85%
OptionableYes Debt/Eq0.00 EPS Q/Q9.00% Profit Margin42.30% Rel Volume1.08 Prev Close201.58
ShortableYes LT Debt/Eq0.06 EarningsJul 29 AMC Payout0.00% Avg Volume2.24M Price198.55
Recom1.80 SMA20-0.40% SMA50-1.13% SMA200-7.72% Volume2,097,231 Change-1.50%
Jul-20-21Downgrade SVB Leerink Mkt Perform → Underperform $170
Jul-19-21Resumed Wolfe Research Outperform $252
Jul-01-21Initiated Raymond James Mkt Perform
Jun-11-21Downgrade Daiwa Securities Outperform → Neutral $210
Feb-23-21Upgrade Robert W. Baird Neutral → Outperform $220 → $252
Feb-02-21Reiterated H.C. Wainwright Buy $315 → $275
Dec-30-20Initiated Daiwa Securities Outperform $250
Nov-30-20Upgrade RBC Capital Mkts Sector Perform → Outperform $247 → $267
Nov-20-20Initiated Bernstein Outperform $225
Oct-28-20Initiated UBS Buy $287
Jul-31-20Reiterated H.C. Wainwright Buy $295 → $315
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $300
Apr-30-20Reiterated H.C. Wainwright Buy $270 → $295
Apr-28-20Downgrade RBC Capital Mkts Outperform → Sector Perform $250 → $260
Mar-04-20Initiated Barclays Overweight $271
Jan-31-20Downgrade Robert W. Baird Outperform → Neutral $210 → $230
Nov-19-19Upgrade Guggenheim Neutral → Buy $252
Nov-12-19Initiated SunTrust Buy $235
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-02-21 07:00AM  
05:52AM  
Jul-31-21 08:37AM  
Jul-30-21 12:31PM  
11:16AM  
10:31AM  
10:02AM  
Jul-29-21 05:25PM  
04:01PM  
Jul-28-21 08:00AM  
05:51AM  
Jul-26-21 12:03PM  
Jul-24-21 05:33AM  
Jul-23-21 12:33PM  
10:20AM  
Jul-22-21 03:03PM  
11:14AM  
Jul-21-21 09:31AM  
07:18AM  
Jul-20-21 05:45PM  
02:06PM  
07:40AM  
06:43AM  
Jul-19-21 11:51PM  
08:00AM  
06:06AM  
Jul-16-21 04:01PM  
11:40AM  
Jul-15-21 08:30AM  
Jul-14-21 05:45PM  
05:51AM  
Jul-13-21 12:45PM  
Jul-07-21 08:04AM  
Jul-06-21 06:30AM  
Jul-05-21 05:50PM  
Jul-04-21 05:51AM  
Jul-03-21 07:01AM  
Jul-01-21 06:09AM  
06:05AM  
Jun-30-21 01:42PM  
06:42AM  
Jun-28-21 05:50PM  
09:26AM  
Jun-25-21 01:44PM  
10:43AM  
Jun-24-21 01:50PM  
05:55AM  
Jun-21-21 05:50PM  
06:06AM  
Jun-18-21 03:50PM  
03:37PM  
Jun-17-21 06:00AM  
Jun-16-21 02:34PM  
06:43AM  
04:49AM  
Jun-15-21 08:35PM  
06:55AM  
05:40AM  
04:37AM  
Jun-14-21 05:50PM  
03:45PM  
10:50AM  
09:38AM  
Jun-11-21 04:15PM  
04:12PM  
01:42PM  
11:35AM  
10:42AM  
10:33AM  
09:24AM  
08:55AM  
08:46AM  
06:45AM  
06:23AM  
05:52AM  
04:36AM  
03:05AM  
02:43AM  
Jun-10-21 06:21PM  
04:03PM  
02:23PM  
12:12PM  
06:06AM  
Jun-09-21 02:37PM  
11:04AM  
08:46AM  
Jun-07-21 05:45PM  
Jun-04-21 05:50PM  
Jun-03-21 10:20AM  
05:51AM  
Jun-02-21 09:03AM  
May-31-21 06:01AM  
May-29-21 08:51AM  
May-26-21 06:10AM  
06:05AM  
May-22-21 06:25AM  
05:51AM  
May-19-21 08:26AM  
06:00AM  
May-18-21 06:43AM  
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bhatia Sangeeta N.DirectorJun 02Sale209.69559117,2165,191Jun 04 04:03 PM
Arbuckle Stuart AEVP, Chief Comm & Ops OfficerMay 17Sale216.4110923,58941,103May 19 04:04 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 17Sale216.367917,09333,589May 19 04:02 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 17Sale216.3411224,23034,108May 19 04:10 PM
Sachdev AmitEVP, Chief Patient OfficerMay 17Sale216.35459,73640,133May 19 04:08 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 03Sale218.43960209,69134,108May 05 09:23 PM
Sachdev AmitEVP, Chief Patient OfficerApr 27Option Exercise86.523,884336,04444,017Apr 29 04:03 PM
Sachdev AmitEVP, Chief Patient OfficerApr 27Sale216.063,884839,19340,133Apr 29 04:03 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 05Sale214.141,686361,04635,834Apr 07 04:04 PM
Liu JoySVP, General CounselMar 05Sale209.695,1411,078,0188,253Mar 08 04:10 PM
Silva Paul MSVP & Chief Accounting OfficerMar 01Sale211.452,782588,2559,884Mar 02 04:07 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 25Sale213.471,080230,55114,884Feb 26 04:23 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 25Sale213.423,586765,30740,133Feb 26 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 25Sale213.383,028646,12530,837Feb 26 04:18 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 25Sale213.543,634775,98941,103Feb 26 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 25Sale213.393,028646,13933,589Feb 26 04:03 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 18Sale211.834,295909,82816,828Feb 19 04:21 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 18Sale211.839,2641,962,36646,665Feb 19 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 18Sale211.837,8251,657,55636,281Feb 19 04:18 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 18Sale211.827,8251,657,48147,635Feb 19 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 18Sale211.837,8251,657,59039,033Feb 19 04:05 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 11Sale210.554,460939,06863,542Feb 16 04:20 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 11Sale210.571,498315,43723,863Feb 16 04:24 PM
Sanna BastianoEVP, Cell & Genetic TherapiesFeb 11Sale210.561,686355,01238,864Feb 16 04:22 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 11Sale210.564,318909,17950,346Feb 16 04:15 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 11Sale210.555,1561,085,59361,700Feb 16 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale210.545,2831,112,27453,098Feb 16 04:02 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 05Option Exercise86.521,930166,98459,157Feb 09 07:44 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 05Sale215.001,930414,95057,227Feb 09 07:44 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 03Option Exercise86.521,554134,45271,511Feb 05 04:43 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 03Option Exercise86.5240034,60857,627Feb 05 04:52 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 03Sale213.741,554332,14669,957Feb 05 04:43 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 03Sale216.5640086,62457,227Feb 05 04:52 PM
Sachdev AmitEVP, Chief Patient OfficerNov 16Sale223.53429,38835,103Nov 18 04:16 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffNov 16Sale223.539120,34126,838Nov 18 04:12 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerNov 16Sale223.6471,56535,179Nov 18 04:11 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 16Sale223.47388,49228,902Nov 18 04:10 PM
SACHS BRUCE IDirectorNov 10Buy217.3615,0003,260,46526,210Nov 12 08:18 AM
Parini MichaelEVP, Chief Adm, Leg & BD OffNov 04Option Exercise86.522,330201,59229,168Nov 06 04:09 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffNov 04Sale217.742,330507,32926,838Nov 06 04:09 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerNov 03Option Exercise86.521,553134,36636,732Nov 05 04:16 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerNov 03Sale211.921,553329,11535,179Nov 05 04:16 PM
Bhatia Sangeeta N.DirectorOct 05Option Exercise126.688,7291,105,79014,424Oct 07 04:11 PM
Bhatia Sangeeta N.DirectorOct 05Sale266.7910,5162,805,5183,908Oct 07 04:11 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 06Option Exercise155.571,223190,26230,125Aug 10 04:13 PM
Kewalramani ReshmaCEO & PresidentAug 06Option Exercise179.682,073372,48228,699Aug 10 04:19 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 06Option Exercise155.571,223190,26228,061Aug 10 04:22 PM
Silva Paul MSVP & ControllerAug 06Option Exercise169.391,078182,59816,010Aug 10 04:24 PM
Silva Paul MSVP & ControllerAug 06Sale271.171,078292,31914,932Aug 10 04:24 PM
Kewalramani ReshmaCEO & PresidentAug 06Sale271.202,073562,20526,626Aug 10 04:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 06Sale271.191,223331,66328,902Aug 10 04:13 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 06Sale271.201,223331,67226,838Aug 10 04:22 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerAug 03Option Exercise86.521,553134,36636,732Aug 05 04:17 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 03Option Exercise86.522,330201,59229,168Aug 05 04:20 PM
Silva Paul MSVP & ControllerAug 03Option Exercise86.5280969,99515,741Aug 05 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59231,232Aug 05 04:14 PM
Sachdev AmitEVP, Chief Patient OfficerAug 03Option Exercise86.521,941167,93537,044Aug 05 04:51 PM
Sachdev AmitEVP, Chief Patient OfficerAug 03Sale278.281,941540,13735,103Aug 05 04:51 PM
Silva Paul MSVP & ControllerAug 03Sale278.30809225,14214,932Aug 05 04:24 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 03Sale278.282,330648,40226,838Aug 05 04:20 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerAug 03Sale278.391,553432,33735,179Aug 05 04:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale278.242,330648,29028,902Aug 05 04:14 PM